Skip to content

mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau

Mimi - mHealth to Increase Measles Immunization. A Randomized Controlled Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02662595
Acronym
mimi
Enrollment
1050
Registered
2016-01-25
Start date
2016-03-31
Completion date
2018-01-31
Last updated
2016-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Measles

Keywords

mHealth, mobile phones, measles vaccination

Brief summary

The question that this project seeks to answer, is whether mobile phones can be used to increase the measles vaccination coverage and timeliness in Guinea-Bissau. The intervention will be evaluated in terms of direct health outcomes and cost/benefit analysis, generating evidence that could help policy makers making informed decisions about implementing mHealth interventions at a national level. The intervention takes the form of a randomized controlled trial in which text messages (SMS) as well as voice calls are scheduled and delivered to mo thers to remind and encourage them to have their children timely vaccinated against measles. In addition, the messages will include relevant information about opening hours and availability of the measles vaccine at the mothers' local health facilities thus improving coordination. The trial will include three different randomization groups with approx. 350 participants in each group. The first group will receive SMS messages, the second group will receive a voice call in addition to the SMS messages, and the third group is a control group that does not receive any intervention. Study participants will be enrolled following birth at one of three health centers in different rural regions of Guinea-Bissau. Before the measles vaccine is scheduled to be given, at 9 months of age, mothers will receive the intervention message depending on their assigned randomization group. When the measles vaccine is administered, the child will be registered as having received the measles vaccination. A follow-up phone interview will be conducted at 12 months of age for all children participating regardless of randomization group and whether or not they received the measles vaccine. All participating children, who at that time still have not received the measles vaccine, will be offered the vaccine at the expense of the project.

Interventions

OTHERSMS reminder message
OTHERVoice call + SMS message

Sponsors

Bandim Health Project
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
No minimum to 3 Months
Healthy volunteers
Yes

Inclusion criteria

* the mother has access to a cell phone (either her own phone or the phone of a household member) * the mother lives in the uptake area of the health center.

Exclusion criteria

* the mother does not have access to a mobile phone.

Design outcomes

Primary

MeasureTime frameDescription
MV Coverage at 12 months of age12 months of ageDifference in measles vaccination coverage at 12 months of age between the intervention and the control groups.

Secondary

MeasureTime frameDescription
TimelinessAt 12 monthsDifference in timeliness of measles vaccines administered, measured as median age of measles vaccinated children.
Average number of visitsAt 12 monthsAverage number of visits to the health center with the purpose of receiving MV needed before MV is successfully administered.

Countries

Guinea-Bissau

Contacts

Primary ContactEmil Rossing, MA
emro@ssi.dk+2455772149
Backup ContactAmabélia Rodrigues, Dr.
a.rodrigues@bandim.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026